NVO: China clears Wegovy for MASH — first GLP-1 RA there for liver

[LondonNewsTrader]

Pharma catalyst overnight: Novo says China NMPA approved Wegovy (semaglutide) for MASH with moderate-to-severe fibrosis — first GLP-1 RA approved for that indication in China, extending the label story beyond weight/CV into liver. Premarket coverage had NVO bid ~1% on the headline.

Scalper framing:
- Label expansion ≠ instant volume; China reimbursement/rollout timing still matters
- Relative tape vs obesity peers (LLY etc.) is the cleaner expression than chasing a one-tick spike
- Keep size small into US open if you’re not already in the name — news was Asia-hours

Source: Reuters (10 Sep 2026) — fair paraphrase.
https://www.reuters.com/business/health ... 026-09-10/

Trading NVO on the China print, or only watching LLY/NVO relative?
Does MASH approval change your bias, or is it already priced as “label stack”?